Nervgen Pharma (NGEN) Net Income (2025 - 2026)
Nervgen Pharma (NGEN) posted quarterly Net Income of -$1.2 million for Q1 2026, up 55.6% year-over-year from -$785254.6 in Q1 2025, and up 55.6% quarter-over-quarter from -$2.8 million in Q1 2025.
Nervgen Pharma (NGEN) Net Income (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Net Income for 2 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income rose 55.6% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$4.0 million (changed N/A YoY), while the FY2025 annual figure was -$31.6 million, down 82.24% from the prior year.
- Net Income rose to -$1.2 million in Q1 2026 per NGEN's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Net Income topped out at -$1.2 million in Q1 2026 and bottomed at -$2.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Nervgen Pharma | 168.94 Mn | 168.94 Mn | - | -21.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.22 Mn |
| Mar 31, 2025 | -2.75 Mn |